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A B S T R A C T
Schizophrenia, depression and posttraumatic stress disorder (PTSD) are severe mental disorders and complicated
diagnostic entities, due to their phenotypic, biological and genetic heterogeneity, unknown etiology, and poorly
understood alterations in biological pathways and biological mechanisms. Disturbed homeostasis between
overproduction of oxidant species, overcoming redox regulation and a lack of cellular antioxidant defenses,
resulting in free radical-mediated pathology and subsequent neurotoxicity contributes to development of de-
pression, schizophrenia and PTSD, their heterogeneous clinical presentation and resistance to treatment.
Metabolomics is a discipline that combines diﬀerent strategies with the aim to extract, detect, identify and
quantify all metabolites that are present in a biological sample and might provide mechanistic insights into the
etiology of various psychiatric disorders. Therefore, oxidative stress research combined with metabolomics
might oﬀer a novel approach in dissecting psychiatric disorders, since these data-driven but not necessarily
hypothesis-driven methods might identify new targets, molecules and pathways responsible for development of
schizophrenia, depression or PTSD. Findings from the oxidative research in psychiatry together with metabo-
lomics data might facilitate development of speciﬁc and validated prognostic, therapeutic and clinical bio-
markers. These methods might reveal bio-signatures of individual patients, leading to individualized treatment
approach. In reviewing ﬁndings related to oxidative stress and metabolomics in selected psychiatric disorders,
we have highlighted how these novel approaches might make a unique contribution to deeper understanding of
psychopathological alterations underlying schizophrenia, depression and PTSD.
1. Psychiatric disorders
Psychiatric disorders such as schizophrenia, depression and post-
traumatic stress disorder (PTSD) are severe mental disorders and
complicated diagnostic entities, due to their phenotypic, biological and
genetic heterogeneity and complex interactions between biological,
environmental and genetic factors that cause development of these
disorders. These disorders have usually unknown etiology, and their
classiﬁcation depends on the particular characteristic symptoms or the
course of illness. Since the biological mechanisms and pathways un-
derlying risk for these disorders are still not completely identiﬁed, there
are no validated, selective and speciﬁc biomarkers for these diseases. To
overcome these obstacles, „omics“ approach was proposed and used.
They were promising approaches, especially genomics, since genome-
wide association studies (GWAS) identiﬁed multiple genetic
associations with psychiatric disorders, indicating a signiﬁcant eﬀect of
heritability [70]. However, due to the polygenic nature of psychiatric
disorders, GWAS indicated many genetic loci but with a ”small eﬀect”,
a questionable clinical signiﬁcance, and limited biological insight [76],
since numerous genetic loci associated with these disorders, biological
pathways and mechanisms are yet not known. Namely, some sub-
stantial loci that might be important as risk factors or contributors for
psychiatric disorders were not detected due to statistical corrections
and cutoﬀs [70]. Besides genomics, other “omics” approaches include
transcriptomics, proteomics and metabolomics (Fig. 1). These im-
portant approaches oﬀer modern state-of-the-art techniques for un-
derstanding biological systems underlying vulnerability to psychiatric
disorders and their interaction with genetic and environmental factors
[83]. These methods use easy available body ﬂuids such as blood,
cerebrospinal ﬂuid (CSF) or urine with a potential clinical utility of
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selected molecules as prognostic, therapeutic and clinical biomarkers
[103].
2. Metabolomics
Metabolomics is a scientiﬁc discipline dealing with small (up to
1.5 kDa) molecules called metabolites. Metabolites are endogenous
low-molecular weight substances synthesized in the cells during meta-
bolic process [26]. Metabolites, such as amino acids, lipids, nucleic
acids, vitamins, carbohydrates and organic acids are the ﬁnal products
of the controlled cellular processes [80,101,106] that are catalyzed by
various enzymes [26]. Similarly to transcriptome and proteome, the set
of these endogenous biomolecules constitute the metabolome [22] that
can be determined on the cellular, tissue, organ or the whole organism
level [34,80]. Unlike genes and proteins, metabolites are much more
diverse, and their variability depends on various genetic and environ-
mental factors [22]. Diﬀerent biological ﬂuids or cell types have a
characteristic set and concentration of metabolites [34]. Therefore, the
balance between metabolites and all enzymes, cofactors, intermediates
and substrates through metabolic pathways is needed to preserve
homeostasis [26]. Metabolites highly reﬂect environmental inﬂuence,
nutrition needs, eﬀects of xenobiotics and medication, stress as well as
diﬀerent pathologies or internal changes in biochemical pathways of
the studied system [76,82]. The metabolome includes all metabolites
that are present in biological samples, such as blood, urine, cell, tissue,
organ or organism, and is a result of the gene x environment interaction
and/or genotype x phenotype interaction [76]. Metabolic processes
reveal the activities of the gene expression and proteins, and metabo-
lome is therefore a product of genome and proteome interacting with
environmental factors, and a regulator of the metabolic homeostasis.
Altered balance in some metabolic pathways leads to metabolic dis-
eases, such as diabetes, atherosclerosis, hypertension and obesity, and
causes a major health problem worldwide [26]. Due to the great im-
portance of metabolites in biological systems, metabolite analysis as a
method is increasingly used in various ﬁelds of research, since it pro-
vides improved understanding of many pathological processes through
altered metabolic pathways [106].
Metabolomics oﬀers mechanistic insights into the etiology of var-
ious diseases [103], providing comprehension of complex interactions
between phenotype and genotype, and it is useful tool for under-
standing how cells and therefore the whole organisms function in
health and diseases [83]. Therefore, metabolomics has a major impact
in pharmacology, environmental sciences, toxicology, cancer, nutrition,
and neuropsychiatry, for detecting potential disease biomarkers
[80,106]. Bioﬂuids used in metabolomics are CSF, plasma, urine, saliva,
bronchoalveolar lavage ﬂuid, digestive ﬂuids, synovial ﬂuid, cyst ﬂuids
and amniotic ﬂuids, while platelets and CSF are the most commonly
used for human metabolomic studies of psychiatric and neurological
diseases [5,80,106].
There are two main approaches to metabolite analysis: i) untargeted
(or non-targeted) metabolomics is the hypothesis generating, global
unbiased analysis of all the small-molecule metabolites present within a
biological system, under a given set of conditions [63]. It usually works
by diﬀerential analysis of two or more groups in a semi-quantitative
manner. This is strict sense what metabolomics means; ii) targeted
metabolomics refers to studies aiming to measure speciﬁc known mo-
lecules, focusing on one or more related metabolic pathways which
have been deﬁned as biologically relevant in previous studies. There-
fore, methods with high levels of speciﬁcity, precision and accuracy are
applied. The potential of metabolomics lies in disease marker discovery
and detection, but also in drug discovery, treatment response and in
markers of toxicity. Altered metabolite levels can be detected at base-
line and after treatment, with the aim to identify speciﬁc metabolites
associated with good or poor therapeutic response, or development of
medication side eﬀects. The extraction, quantiﬁcation, identiﬁcation
and interpretation of diﬀerent metabolites require sophisticated ana-
lytical technologies, statistical methods for data interpretation, as well
as bio-statistical and multi-variant methods [9,43,82]. Analytical
techniques, including mass spectrometry (MS), coupled to diﬀerent
separation techniques and nuclear magnetic resonance (NMR) produce
data on a large number of metabolites (Table 1), although additional
technologies are required for metabolites that appear and act at lower
concentrations [26]. Therefore, most data on all metabolites from a
single sample are obtained from diﬀerent analytical platforms. MS/
chromatography and NMR are basic strategies for metabolomics
[26,34,91].
While MS relies on mass to charge ratio of ionized particles, NMR
spectroscopy uses magnetic properties of certain nuclei, such as 1H, 13C,
Fig. 1. Omics approach to psychiatric disorders.
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31P and some others [106]. NMR spectroscopy is a reproducible and
quantitative technique with low sensitivity. Mass spectrometers can
detect low-concentration metabolites, but unlike NMR, MS quantitation
is not so straightforward. MS is a powerful analytical platform whose
eﬃciency is increased by coupling with the separation techniques, GC
or LC or capillary electrophoresis. The main advantage of GC-MS lies in
the fact that it enables compound identiﬁcation according to both, re-
tention time and mass spectrum [53]. Namely, it gives highly re-
producible retention time proﬁles and fragmentation spectra. This is a
valuable feature which enables users to use standard libraries, such as
National Institute of Standard Technologies library (NIST) or Fiehn
retention time locked library [46], as well as to build and share their
own databases making the identiﬁcation of compounds less demanding
[74]. There are also some limitations of GC-MS. Since volatility of
compounds is obligatory for GC-MS, this method usually starts with
demanding sample treatment, including the removing of non-volatile
compounds and derivatization process, which enables non-volatile
compounds to become volatile [17]. At the end, a limited subset of
compounds, usually organic acids, amino acids, mono- and di-sac-
charides, various clases of lipids and sterols can be analyzed by this
method [37]. Sample treatment for LC-MS is usually less demanding
and this analytical method can be also used for the analysis of non-
volatile and thermally fragile molecules [113]. For example, semi-polar
compounds, such as phenolic acids, ﬂavonoids and glycosylated species
are separated using reverse phase liquid chromatography (RPLC), but
also non-polar compounds as most of lipids. Hydrophilic interaction
liquid chromatography (HILIC) is used for analyzing polar compounds
like sugars, amino acids, vitamins, carboxylic acids and nucleotides.
Although LC-MS has broader use than GC-MS, the identiﬁcation of
compounds in LC-MS is more challenging. It is mostly putative identi-
ﬁcation starting with mass-based search against databases [27] often
followed by tandem MS experiments or MS experiments with sample
and authentic compound whose presence in the sample needs to be
conﬁrmed [92]. In capillary electrophoresis, separation of compounds
happens according to the diﬀerences in their intrinsic electrophoretic
mobility, depending on their charge and size [44]. Therefore, it is more
suitable for the analysis of polar and charged metabolites such as amino
acids. Although it is technically more demanding, with lower con-
centration sensitivity and higher migration time variability, it is still
highly used for reproducible proﬁling of native peptides [75] and sec-
ondary metabolites. However, in order to expand metabolite coverage
for untargeted metabolomics a combination of diﬀerent analytical
platforms is highly recommended [62]. Beside compound detection,
identiﬁcation and quantiﬁcation, univariate (t-test, fold-change ana-
lysis, Wilcoxon rank sum test, analysis of variance) and multivariate,
both unsupervised (principal component analysis) and supervised
(partial least square-discriminant analysis), methods for statistical
analysis are applied to detect those compounds whose levels are sig-
niﬁcantly diﬀerent between distinct biological groups [98,102]. In the
last step, the compounds of interest should be placed in right biological
context by performing a pathway analysis which implies assembling of
metabolite sets according to available public databases such as Human
Metabolome Data Base, The Small Molecule Pathway Database, Kyoto
Encyclopedia of Genes and Genomes and others [39,99] and text-
mining of literature. At the end, the main goal is to identify a biological
pathway included in disease condition or potential reliable biomarker,
which can be further investigated (Fig. 2).
2.1. Oxidative stress
Oxidative stress is characterized by the loss of homeostasis between
overproduction of reactive oxygen species (ROS), and a lack of cellular
antioxidant defenses going beyond the normal redox regulation
[20,89]. Oxidative stress cascade results in oxidative stress damage,
which targets proteins, lipids and DNA. This process contributes to
numerous pathological conditions, such as cancer, cardiovascular, re-
spiratory and metabolic diseases, neurodegenerative and psychiatric
disorders. Normal cellular metabolism results in production of ROS,
which are under control of major antioxidants including superoxide
dismutase, catalase, glutathione peroxidase, glutathione, uric acid, vi-
tamin C, vitamin E, carotene and albumin [20]. However, under
chronic oxidative stress, ROS-damaged biomolecules accumulate in the
aﬀected cells and in the entire organism, consequently aﬀecting the
metabolism [30,68]. Thus, oxidative stress results in protein, lipid,
carbohydrate and nucleic acid alterations leading to apoptosis, necrosis
and other structural cell damages and modiﬁcations [66]. Metabolites,
intermediates, enzymes and their activity in many metabolic pathways
are altered due to high rates of ROS that can have both beneﬁcial and
harmful eﬀects on target cells or tissues [35,48]. ROS and reactive ni-
trogen species (RNS) are associated with various processes in the or-
ganism, such as lipid peroxidation, activation of phagocytes, trauma,
Table 1
Comparison of diﬀerent analytical techniques in metabolomics.
ANALYTICAL TECHNIQUES
NMR MS
Principle of
detection
Magnetic
properties of
atomic
nuclei (1H,
13C, 31P)
Mass to charge ratio of ionized particles
LC GC CE
Sample
preparation
+ + - +
Reproducibility/
robustness
+ - + -
Sensitivity - + + -
Types of
components
Polar and
non-polar
Broad use
depending
on LC type
Thermostable
and volatile
molecules
Polar
charged
molecules
Fig. 2. Metabolomics workﬂow.
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oxidative phosphorylation, ischemia, etc. [35,99]. Oxidative status of
the organism and levels of ROS can be evaluated by indirect measure-
ment of the oxidative products, enzymes and antioxidant levels in the
brain or on the periphery. Oxidative stress induces neurochemical and
neuroanatomical changes and it is involved in many psychiatric and
neurodegenerative diseases, such as schizophrenia, Alzheimer's, Par-
kinson's and Huntington's disease [12,57,66].
Among speciﬁc pathophysiological features of oxidative stress, in
particular of acute disorders, are alterations of the blood: brain barrier,
which becomes permeable upon inﬂuences of the lipid peroxidation
product 4-hydroxynonenal (HNE) causing inﬂammatory response re-
sulting in systemic stress response [55,84,105]. However, while neu-
ropathological aspects of oxidative stress and in particular of lipid
peroxidation in neurodegenerative diseases were intensively studied,
thus contributing to the modern concepts of major human diseases
[104], the association of neuronal and systemic oxidative stress and
lipid peroxidation with psychiatric diseases are less known and need
more intense studies implementing modern concepts of integrative,
personalized medicine [85].
2.2. Schizophrenia
Schizophrenia is a severe chronic mental, but also neurodevelop-
mental disorder, with a complex presentation and complicated and
diverse symptoms. It is assumed that ~1% of the people worldwide
have schizophrenia [8]. The disorder is characterized by diﬀerent
clusters of symptoms that might be subdivided into positive, negative,
cognitive and mood (depressive) symptoms [2,3,24]. It is highly heri-
table and polygenic, with heterogeneous underlying neurobiology, and
with poorly understood etiology [67]. Combination of various en-
vironmental factors (early life experience, exposure to violence, can-
nabis, drug abuse, migration, etc.) and their interactions with diﬀerent
genetic variations, but also epigenetic inﬂuences contribute to schizo-
phrenia development [67,76]. Although GWAS oﬀered some novel
genetic loci associated with schizophrenia, the problem is frequent non-
replication and limited reproducible ﬁndings of these data, due to
schizophrenia's phenotypic, genotypic, biological, but also clinical
heterogeneity.
2.3. Schizophrenia and oxidative stress
Oxidative stress has been revealed as one of the biological under-
pinning of the pathophysiology of schizophrenia [20,7]. Namely, it is
tightly associated with inﬂammation, which generates ROS. Dysregu-
lation of the redox balance during neurodevelopment might damage
neurons, compromise neuronal survival, induce interneuron deﬁcits via
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, elicit
oligodendrocyte abnormalities, impair GABA interneurons, and aﬀect
biochemical processes that cause neuronal dysfunction, mitochondrial
dysfunction, aﬀect activity of the N-methyl-D-aspartate receptors and
produce aberrant inﬂammatory responses [20,7]. Markers of oxidative
stress damage could be detected early in prodromal stage of schizo-
phrenia; therefore, oxidative stress markers might be used to improve
early diagnostic procedures, detection and interventions, and to ad-
vance treatment outcome [20,7]. In patients with schizophrenia,
homocysteine, a marker of the oxidative stress, was found to be asso-
ciated with the severity of the positive, negative, cognitive and de-
pressive symptoms, and with poor functioning [29].
2.4. Metabolomics in schizophrenia
Metabolomic studies in schizophrenia are complicated by the clin-
ical heterogeneity of the schizophrenia symptoms and diﬀerent treat-
ment options. To avoid these confounders, the ﬁrst episode of psychosis
(i.e. in drug naive patients) could be evaluated. In this group, several
metabolic disturbances in plasma or urine were found [11]. These
metabolites were associated with neurotransmitter, amino acid, glucose
and energy metabolism imbalances, oxidative stress and lipid metabo-
lism disturbances, disruptions in antioxidant defense system, bowel
microﬂora and endocrine system in schizophrenia patients [11]. De-
tailed metabolomic analysis revealed altered levels of noradrenergic
metabolites (noradrenaline, vanil-mandelic acid, 3-methoxy-4-hydro-
xyphenylglycol), increased levels of plasma alanine, glycine and urine
valine and glycine levels, as well as reduced levels of fasting plasma
glucose, phosphatidylcholine, high-, low- and very low-density lipo-
proteins, unsaturated fatty acids and lipids; decreased levels of citrate,
α-KG, creatine and creatinine, acetoacetate and 3-hydroxybutyrate and
elevated levels of lactate and lysophosphatidylcholines in ﬁrst-episode
neuroleptic-naïve schizophrenia patients [11]. Biomarkers of the ele-
vated oxidative stress were lower levels of antioxidants uric acid and
taurine, but also increased lysophosphatidylcholines that transfer to
phosphatidylcholines during the oxidation of LDL cholesterol, con-
tributing to the development of cardiovascular and metabolic diseases
and metabolic syndrome in schizophrenia [11]. Targeted metabolomic
approach to schizophrenia revealed ﬁve metabolites: higher con-
centration of ornithine and lower concentration of arginine, glutamine,
histidine and one lipid (PC ae C38:6), which could be used as bio-
markers of schizophrenia since they were signiﬁcantly diﬀerent from
values in controls and were not aﬀected by antipsychotic medication
[32]. In addition, these metabolites were associated with 13 risk genes
for schizophrenia including gene coding for nitric oxide synthase 1,
transcription factor 4, neurotrophin receptor kinase 3, catechol-O-me-
thyltransferase, mitochondrial proline dehydrogenase, leucine carboxyl
methyltransferase 1, cytosolic purine 50-nucleotidase, DNA-directed
RNA polymerase III subunit RPC3, integrin beta-1, integrin alpha-10,
clathrin, heavy chain-like 1, cell division control protein 42 homolog
and cut-like homeobox 1 [32]. These associations are in line with stu-
dies suggesting genetic susceptibility of schizophrenia. Observed dif-
ferentiating metabolites were primarily related to altered glutamine
and arginine metabolism, disturbed biosynthetic process of nitrogen
compounds, impaired learning memory, immune and immune-related
signaling and neurotrophin signaling pathways [32]. Therefore, these
metabolomic markers might be used as theranostic biomarkers of
schizophrenia [32]. A detailed metabolomic study indicated that
pathways involved in glucoregulation and proline metabolism were
aﬀected in schizophrenia [71]. Namely, the combination of selected
metabolites associated with proline- and insulin-related changes were
conﬁrmed with higher metabolite levels of saturated triglycerides,
branched chain amino acids, phenylalanine and tyrosine, and proline,
glutamic, lactic and pyruvic acids found in schizophrenia patients in
comparison to controls [71]. This study conﬁrmed the usefulness of
metabolomics as a powerful tool in dissecting illness pathways of
schizophrenia. Changes, such as increases and decreases of various
metabolite levels in schizophrenia are presented in Table 2.
3. Depression
Depression is complex and clinically heterogeneous psychiatric
disorder aﬀecting 10–15% of people during lifetime and representing
one of the main causes of disability and suicide [15]. Relatively low
eﬃcacy of treatment response (< 50%) to antidepressant drugs is
probably due to a lack of well-characterized depression biomarkers.
Although GWAS failed to identify genetic loci associated with depres-
sion [90], various research suggests strong interaction between genes
and environment. The factors aﬀecting nervous, endocrine, metabolic
and immune systems and consequently inﬂuencing the development of
depression include genetic and epigenetic factors, sex, hypothalamic-
pituitary-adrenal (HPA) axis reactivity, as well as environmental in-
ﬂuences such as toxins, early life adversities, socioeconomic status and
stress [52]. Therefore, the analysis of metabolomics data might con-
tribute to a better stratiﬁcation of depressive subtypes and elucidation
of complex interactions between genes and environment [76].
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3.1. Depression and oxidative stress
Various studies demonstrated the involvement of oxidative stress in
depression, as evidenced by observed elevated lipid peroxidation,
higher generation of ROS and dysfunction of mitochondria [1,47]. In
patients with depression, both increased ROS production and its im-
paired neutralization by antioxidant and detoxiﬁcation mechanisms
were found [54]. This oxidant-antioxidant imbalance in depression may
result in higher damage of various biomolecules, including DNA [14].
However, in addition to oxidative stress, increased DNA damage might
be due to a less eﬃcient DNA damage repair [14]. Further studies in-
cluding metabolomics approaches could help to elucidate the exact
mechanisms underlying altered oxidative status as well as usefulness of
oxidative stress biomarkers in depression.
3.2. Metabolomics in depression
Increased plasma lysophospholipids, monoglycerophospholipids
and phosphatidyle-thanolamines, which are involved in important cell
processes such as energy storage, membrane integrity, as well as cell
signaling, survival and apoptosis, have been found in depressive pa-
tients [49], together with decreased levels of free fatty acids. On the
other hand, treatment with antidepressant drugs produced increased
release of lysophospholipids in the mouse brain (Lee et al., 2009).
Lower levels of diﬀerent acyl carnitine molecules, observed in plasma of
subjects with depression, could be used as possible biomarkers of de-
pression [49]. Acetyl-l-carnitine might be eﬀective for treatment of
depression [95]. Carnitine molecules are very important for the trans-
port of a long chain fatty acyl group across the inner mitochondrial
membrane. Reduced plasma concentrations of stearic and palmitic
amide, as well as lithocholic, deoxycholic, glycodesoxycholic, gly-
coursodeoxycholic and taurochenodeoxycholic acid were found in de-
pression [49]. Palmitic acid induces anxiety-like behaviors in animals
[59], whereas decreased palmitic acid brain levels are associated with
anxiolytic eﬀects [86]. In contrast to palmitic acid-induced reduction of
proliferation of neuronal progenitor cells [73], stearic, glycourso-
deoxycholic and taurochenodeoxycholic acids were shown to exert
neuroprotective eﬀects [69,94,96]. Results demonstrating higher serum
glutamate and aspartate levels in depression suggest possible abnorm-
alities in amino-acid pathway of the urea cycle in the liver or the dis-
ruption of NMDA receptor function [49]. The elevated levels of alanine,
taurine, citrate, formate, glycine, isobutyrate and nicotinate, involved
in the gluconeogenesis and fatty acid synthesis, have been observed in
the urine of patients with depression [112]. In addition to the increase
of these amino acids, lower levels of plasma or urine glucose, lactate,
and pyruvate as well as increased levels of α-ketoglutarate, succinate,
malonate, methylmalonate, and succinyl-CoA further supported the
imbalance between glycolysis and gluconeogenesis and shift toward
fatty acid and/or amino acid catabolism in depression [111,112]. A
decrease in tryptophan and tyrosine levels found in depression
[49,52,60], might also suggest increased conversion to serotonin and
cateholamines such as dopamine, norepinephrine and epinephrine or
deﬁcit in protein catabolism. Lower CSF levels of 5-hydroxyindoleacetic
acid (5-HIAA) and homovanillic acid (HVA), which are serotonin, do-
pamine, and norepinephrine metabolites, implied altered serotonin and
dopamine functions in depressed patients [4]. Metabolites from tryp-
tophan, tyrosine and methionine pathways might be useful for diﬀer-
entiation between remitted and non-remitted depression [38]; how-
ever, the results regarding methionine plasma levels in depressive
patients are contradictory [49,100]. Decreased concentrations of N-
methylnicotinamide in depression [112] might suggest the deﬁciency of
nicotinamide, important for coenzymes in oxidation-reduction reac-
tions. [111] and 23 urinary metabolites (2013b) altered in depressed
patients, and proposed a panel of 6 urinary metabolites (sorbitol, uric
acid, azelaic acid, quinolinic acid, hippuric acid, and tyrosine) as can-
didate diagnostic biomarkers for depression [109]. Finally, the same
group of authors [110] also proposed metabolite signature from per-
ipheral blood mononuclear cells composed from 17 metabolites mainly
involved in disturbances of energy and neurotransmitter metabolism,
which could distinguish depressed patients not only from healthy
controls but also from schizophrenia subjects (Table 3).
3.3. Posttraumatic stress disorder
Posttraumatic stress disorder (PTSD) is a common, prevalent, se-
vere, disabling and debilitating mental disorder causing a response of
helplessness, intense fear and horror. It develops in some, but not all
persons after traumatic exposure. PTSD is trauma- and stressor-related
disorder in which direct exposure of traumatic experience or stressful
event leads to an onset of symptoms: re-experiencing, avoidance,
numbing and hyper-arousal. Such psychological trauma has impact on
molecular, cellular and organic systems of the individual [6,78,107].
PTSD is frequent worldwide, with varying lifetime prevalence from 8%
in USA [45] to 18% in Croatia [81]. Its etiology is still not clear, but
Table 2
Altered metabolite levels in schizophrenia.
PSYCHIATRIC DISEASE METABOLOMICS REFERENCES
Increased levels ↑ Decreased levels ↓
Schizophrenia Alanine Glucose [11,32,71]
Glycine Phosphatidylcholine
Valine (urine) HDL
Glycine (urine) LDL
Lactate VLDL
Lysophosphatidylcholines Unsaturated fatty acids
Ornithine Lipids
3-Indolebutyrate (microﬂora) Citrate
Phenylalanine α-KG
Tyrosine Creatine
Proline Creatinine
Glutamic acid Acetoacetate
Pyruvic acid 3-Hydroxybutyrate
Saturated triglycerides Arginine
Glutamine
Histidine
Ketone bodies
Hippurate (microﬂora)
Trimethylamine-N-oxide (microﬂora)
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psychological trauma impacts molecular, cellular and organic systems
of the individual [6,16,78,87,107]. Development of PTSD is facilitated
by the presence of diﬀerent risk factors such as female gender, severity,
duration and number of traumatic incidents, childhood abuse and ne-
glect, lack of family and social support and existence of previous mental
disorders [114]. Since not all subjects exposed to a traumatic event
develop PTSD, the extent to which individuals are vulnerable or re-
silient to trauma depends on a number of factors, primarily trauma
related, psychosocial, biological, environmental, genetic and epigenetic
factors, and the interaction between them. Biological changes in PTSD
are systemic [56] and include altered HPA axis function and immune,
neurotransmitter and neurotrophic functions, increased thyroid ac-
tivity, high sensitization of the nervous system, reduction in prefrontal
brain regions, lower hippocampal volume, increased activity of amyg-
dala, enhanced risk of cardiovascular, metabolic and autoimmune dis-
eases, but also accelerated age-related processes, such as altered N-
glycosylation, increased DNA damage and shortened telomeres
[42,56,61,78,88].
3.4. PTSD and oxidative stress
Biochemical data and animal studies point to possible role of oxi-
dative stress in stress-related and anxiety disorders. Therefore, it is
assumed that changes induced by the oxidative stress can be found in
PTSD. Traumatic stress causes changes in physical appearance, and
alterations on skin and hair appear in aﬀected subjects, similarly as
after the eﬀects of oxidative stress [57]. While sleep disturbances are
characteristic features of PTSD, animal studies have shown that sleep
deprivation among rats causes oxidative stress, and has a major impact
on memory and anxiety behavior [57]. Human studies failed to ﬁnd a
clear association between oxidative stress biomarkers and PTSD
[12,92]. In Croatian war veterans with combat related PTSD, a lack of
signiﬁcant association between PTSD and urinary concentrations of 8-
OHdG, serum thromboxane B2, and serum urates. However, sig-
niﬁcantly lower levels of protein carbonyls were found in the PTSD
group than in the control group [12]. Although the nominal diﬀerences
in serum concentration of protein carbonyls, albumins and total pro-
teins were found between subjects with PTSD and control subjects,
since subjects with PTSD had signiﬁcantly lower concentrations than
control group, these diﬀerences disappeared when evaluated using the
receiver operating characteristic ROC analysis as a graphical plot that
illustrates the diagnostic ability for the binary system which has vari-
able discrimination threshold. The ROC curves did not separate the
groups satisfactory, and ROC analysis revealed excess of false negative
and false positive results for protein carbonyls, total proteins and al-
bumin [12]. Another study found that a product of lipid peroxidation,
malondialdehyde (MDA) is not associated with PTSD [92]. Hence,
further studies are needed to clarify the role of oxidative stress in PTSD
[57]. Such a confusing ﬁndings indicating possible negative association
of oxidative protein modiﬁcations and no MDA and 8-OHdG changes in
PTSD indicate the need to study in particular the metabolism of HNE
and the levels of HNE-His adducts in PTSD patients. Namely, the as-
sociation of HNE and in particular its adducts to proteins, such as al-
bumin, were found to be potentially very reliable biomarker of tissue
speciﬁc and systemic lipid peroxidation associated with metabolic
disorders, cancer and inﬂammatory processes including neuroborre-
liosis and encephalitis, which were found to be associated with systemic
metabolic alterations, both reﬂecting like HNE-His disease progression
and the eﬃcacy of therapies used [19,25,36,50,51,58,77,97].
3.5. Metabolomics in PTSD
Animal studies have shown altered citric acid cycle and myelination
pathway, i.e. glutamate, alanine, aspartate, glyoxylate, citric acid cycle
and dicarboxylate metabolism pathways were involved in the hyper-
arousal among shocked mice [41]. Furthermore, metabolites, such as
sarcosine, kynurenic acid, nicotinate and xanthurenic acid were cor-
related with behavioral changes in stressed mice [40], while inter-
mediates involved in the process of citric acid cycle, such as citric,
isocitric, aconitic, succinic and oxalacetic acids were decreased in
shocked mice [41]. To our knowledge, only one preliminary study [42]
analyzed metabolites in a small number of PTSD subjects: in 20 PTSD
patients and 18 controls. They discovered 13 changed metabolites, in-
cluding one metabolite in endocannabinoid signaling and four glycer-
ophospholipids among PTSD patients. Metabolites were classiﬁed as
monosaccharides, fatty acids metabolites, glycerophospholipids, bile
acids, nucleosides, anti-oxidants and phospholipids [42]. N-acet-
ylglucosamine-6-phosphate, palmitoylethanolamide, palmitic amide,
guanosine, inosine and pantothenic acid were down-regulated among
PTSD patients, while concentrations of glycerophosphoethanolamines
Table 3
Altered metabolite levels in depression.
PSYCHIATRIC DISEASE METABOLOMICS REFERENCES
Increased levels ↑ Decreased levels ↓
Depression Lysophospholipids
Monoglycerophospholipids
Phosphatidylethanolamines
Glutamate (serum)
Aspartate (serum)
Alanine
Taurine
Citrate
Formate
Glycine
Isobutyrate
Nicotinate
α-KG
Succinate
Malonate
Methylmalonate
Succinyl-CoA
γ-aminobutyric acid
Acyl carnitine Molecules
Stearic amide
Palmitic amide
Lithocholic acid
Deoxycholic acid
Glycodesoxycholic acid
Glycoursodeoxycholic acid
Taurochenodeoxycholic acid
Glucose
Lactate
Pyruvate
Tryptophan
Tyrosine
5-Hydroxyindoleacetic acid (CSF)
Homovanillic acid (CSF)
N-methylnicotinamide
Isoleucine
Valine
Dopamine
Ribulose 5-phosphate
Malic acid
Fumaric acid
[49,112,111,60,4,110]
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in serum were increased in subjects with PTSD compared to control
subjects. Guanosine and inosine showed the strong relationship with
PTSD symptomatology, suggesting that these altered metabolites have
dose-dependent relationship with PTSD symptoms. In this study [42]
four glycerophospholipids that are involved in neuro-inﬂammation and
alterations in cell membrane dynamics and metabolism, were increased
in PTSD. Fatty acid metabolites palmitoylethanolamide and palmitic
amide, responsible for the energy metabolism, signaling, en-
docannabinoid system and stress responses, were decreased in PTSD.
Nucleosides, guanosine and inosine were reduced in PTSD, and these
metabolites have important roles in central nervous system, sleep and
memory. Key signaling molecules, regulators of lipid, glucose and en-
ergy metabolism and bile acids were also altered in PTSD: 3α-hydroxy-
5β-cholan-24-oic acid and glycocholic acid levels were lower, while
7α,12α-dihydroxy-3-oxocholest-4-en-26-oic acid was higher in PTSD.
Out of monosaccharides, N-acetylglucosamine-6-phosphate, a precursor
of uridine diphosphate N-acetylglucosamine, was decreased in PTSD
[42], and this ﬁnding might explain why subjects with PTSD develop
frequently autoimmune and inﬂammatory diseases [10]. In line with
these ﬁndings, anti-oxidant, pantothenic acid, was decreased in PTSD.
Antioxidants are important as they protect from oxidative processes and
oxidative damage or age-induced damages. Metabolites associated with
PTSD (Table 4) are also involved in several biological processes, such as
biological aging, oxidative stress, inﬂammation, metabolism, auto-
immune reactions and cellular signaling.
In addition, metabolites have a major impact as signaling molecules,
energy sources and membrane components on many psychopatholo-
gical processes. Down-regulation of these metabolites is linked with
speciﬁc symptoms and proposed theory that endocannabinoid system is
associated with PTSD [42]. PTSD has been also associated with in-
creased inﬂammatory response and production of pro-inﬂammatory
cytokines [28,56,72], while palmitoylethanolamide has been nega-
tively associated with PTSD [31,33,64]. Therefore, all these data reveal
that detected altered metabolites might have important role in devel-
opment of PTSD and that metabolomics-related multidimensional data
should be used to discover perturbed biological networks aﬀected by
traumatic experiences [65].
Common metabolites that are altered in depression, schizophrenia
and PTSD are shown in Table 5. As can be concluded from this short
overview, there are (as far as we are aware) no common metabolites for
all three psychiatric disorders (depression, schizophrenia and PTSD).
However, depression and schizophrenia share only two metabolites,
glutamate and glycine, which are both increased in these disorders.
Palmitic amide was the only shared metabolite decreased in both de-
pression and PTSD (Table 5).
4. Conclusion
Novel evidence reveals that disruption of the homeostasis
mechanisms, the onset of chronic oxidative stress, free radical-mediated
pathology and subsequent neurotoxicity contributes to development of
depression, schizophrenia and PTSD, their diverse clinical symptoms
and poor treatment response [108]. Add-on treatments based on stra-
tegies aimed to target oxidative/nitrosative stress and to provide anti-
oxidant supplementation may improve treatment options and conﬁrm
the signiﬁcant role of oxidative stress in the biological/biochemical
underpinning of these disorders [108]. Oxidative stress research,
combined with metabolomics, is a promising approach in dissecting
psychiatric disorders, since these data-driven, but not necessarily hy-
pothesis-driven methods might identify new molecules and molecular
pathways and circuits associated with complex phenotypes such as
schizophrenia, depression or PTSD [65]. Metabolomics might facilitate
development of individualized treatment approach and help in identi-
fying medication that would normalize dysregulated molecular net-
works in these disorders, predict good or poor response to treatment or
development of side eﬀects as well as oﬀer theranostic biomarkers and
reveal bio-signatures of individual patients, leading to a personalized
medicine approach [65], thus supporting also the novel paradigm of
pathophysiology of lipid peroxidation [21,79] and modern concepts for
the use of oxidative stress biomarkers to monitor major human diseases
[13,18,23]. In all these considerations it has to be taken into account
that for most of the psychiatric disorders metabolomic approaches can
only be performed in blood or CSF specimen. Rarely do we get a direct
insight into the cellular metabolites during psychiatric processes.
Therefore, only a combination of human studies and representative
animal models, combined with “omics” approaches can lead to further
insight into such diseases and advance novel treatment strategies.
Table 4
Altered metabolite levels in PTSD.
PSYCHIATRIC DISEASE METABOLOMICS REFERENCES
Increased levels ↑ Decreased levels ↓
PTSD Glycerophosphoethanolamines (serum) Citric acid (mice) Isocitric acid (mice) [42,41,31,33,64]
Glycerophospholipids Aconitic acid (mice)
7α,12α-dihydroxy-3-oxocholest-4-en-26-oic acid Succinic acid (mice)
Oxalacetic acid (mice)
N-acetylglucosamine-6-Phosphate,
Palmitoylethanolamide
Palmitic amide
Guanosine
Inosine
Pantothenic acid
3α-hydroxy-5β-cholan-24-Oic acid
Glycocholic acid
Table 5
Common metabolites altered in schizophrenia, depression and PTSD.
METABOLITES PSYCHIATRIC DISEASE
Schizophrenia Depression PTSD
Alanine - - ND
α-KG - + ND
Citrate - + - (mice)
Glucose - - ND
Glutamate + + ND
Glycerophospholipids + ND +
Glycine + + ND
Lactate + - ND
Palmitic amide - + +
Pyruvate + - ND
Succinate ND + - (mice)
Tyrosine + - ND
Valine + - ND
+ (increased levels); - (decreased levels); ND (not detected).
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